Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
Investors
（02186.HK）
HK$
➚
%
Volume(M)
0thousand
Turnover(HK $)
0thousand
Data as of：
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Year
2022
2023
2024
2025
2026
Search
14
2026-08
VOLUNTARY ANNOUNCEMENT COMPLETION OF PHASE IA CLINICAL TRIAL OF BA1302 (CD228-DIRECTED ADC) IN CHINA
14
2026-08
INSIDE INFORMATION ANNOUNCEMENT PROFIT WARNING
14
2026-08
NOTICE OF BOARD MEETING
06
2026-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2026
05
2026-08
VOLUNTARY ANNOUNCEMENT BLA SUBMISSION FOR AFLIBERCEPT INTRAVITREOUS INJECTION IN BRAZIL
08
2026-07
VOLUNTARY ANNOUNCEMENT CDE ACCEPTANCE OF IND APPLICATION FOR BA1203 (A MASKED ANTI-PD-1/IL-2 FUSION PROTEIN)
06
2026-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2026
02
2026-07
VOLUNTARY ANNOUNCEMENT CDE APPROVAL OF PHASE II CLINICAL TRIAL APPLICATION FOR BA1106 IN COMBINATION WITH BA1104 FOR NSCLC
22
2026-06
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 JUNE 2026
11
2026-06
VOLUNTARY ANNOUNCEMENT LICENSING OF DULAGLUTIDE INJECTION IN THE U.S.
1
2
3
4
5
Follow me
鲁公网安备37069102000284
ICP备：鲁ICP备2021004064号-1
